160 related articles for article (PubMed ID: 20503394)
1. CYP17 polymorphisms and prostate cancer outcomes.
Wright JL; Kwon EM; Lin DW; Kolb S; Koopmeiners JS; Feng Z; Ostrander EA; Stanford JL
Prostate; 2010 Jul; 70(10):1094-101. PubMed ID: 20503394
[TBL] [Abstract][Full Text] [Related]
2. CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population.
Souiden Y; Mahdouani M; Chaieb K; Elkamel R; Mahdouani K
Cancer Epidemiol; 2011 Oct; 35(5):480-4. PubMed ID: 21193363
[TBL] [Abstract][Full Text] [Related]
3. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
4. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
Shui IM; Lindström S; Kibel AS; Berndt SI; Campa D; Gerke T; Penney KL; Albanes D; Berg C; Bueno-de-Mesquita HB; Chanock S; Crawford ED; Diver WR; Gapstur SM; Gaziano JM; Giles GG; Henderson B; Hoover R; Johansson M; Le Marchand L; Ma J; Navarro C; Overvad K; Schumacher FR; Severi G; Siddiq A; Stampfer M; Stevens VL; Travis RC; Trichopoulos D; Vineis P; Mucci LA; Yeager M; Giovannucci E; Kraft P
Eur Urol; 2014 Jun; 65(6):1069-75. PubMed ID: 24411283
[TBL] [Abstract][Full Text] [Related]
6. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
Setiawan VW; Schumacher FR; Haiman CA; Stram DO; Albanes D; Altshuler D; Berglund G; Buring J; Calle EE; Clavel-Chapelon F; Cox DG; Gaziano JM; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn J; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Kraft P; Ma J; Le Marchand L; Linseisen J; Lund E; Navarro C; Overvad K; Palli D; Peeters PH; Pike MC; Riboli E; Stampfer MJ; Thun MJ; Travis R; Trichopoulos D; Yeager M; Ziegler RG; Spencer Feigelson H; Chanock SJ
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2237-46. PubMed ID: 18006912
[TBL] [Abstract][Full Text] [Related]
7. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer associated with CYP17 genotype.
Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E
Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.
Taioli E; Sears V; Watson A; Flores-Obando RE; Jackson MD; Ukoli FA; de Syllos Cólus IM; Fernandez P; McFarlane-Anderson N; Ostrander EA; Rodrigues IS; Stanford JL; Taylor JA; Tulloch-Reid M; Ragin CC
Prostate; 2013 May; 73(6):668-76. PubMed ID: 23129512
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
12. CYP17 gene promoter allelic variant is not associated with prostate cancer.
Lin CC; Wu HC; Chen WC; Chen HY; Tsai FJ
Urol Oncol; 2003; 21(4):262-5. PubMed ID: 12954495
[TBL] [Abstract][Full Text] [Related]
13. A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051
[TBL] [Abstract][Full Text] [Related]
14. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
Tigli H; Yazici H; Dalay N
Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
[TBL] [Abstract][Full Text] [Related]
15. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Hamada A; Danesi R; Price DK; Sissung T; Chau C; Venzon D; Sparreboom A; Dahut WL; Figg WD
Urology; 2007 Aug; 70(2):217-20. PubMed ID: 17826473
[TBL] [Abstract][Full Text] [Related]
16. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans.
Kittles RA; Panguluri RK; Chen W; Massac A; Ahaghotu C; Jackson A; Ukoli F; Adams-Campbell L; Isaacs W; Dunston GM
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):943-7. PubMed ID: 11535545
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
18. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer.
Chang B; Zheng SL; Isaacs SD; Wiley KE; Carpten JD; Hawkins GA; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB; Xu J
Int J Cancer; 2001 Nov; 95(6):354-9. PubMed ID: 11668516
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
Cai L; Huang W; Chou KC
Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Sarma AV; Dunn RL; Lange LA; Ray A; Wang Y; Lange EM; Cooney KA
Prostate; 2008 Feb; 68(3):296-305. PubMed ID: 18163429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]